Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit, Guangdong Hengrui Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trial of recaticimab injection, according to a Shanghai bourse filing on Wednesday.
The drug is used to treat adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrent stroke.
The pharmaceutical company invested 422.2 million yuan into the research and development of the drug.
The company's Hong Kong shares rose 2% during the morning trade.